Patrys raises $3.4m to fund product trials
Monday, 05 December, 2011
Melbourne-based Patrys (ASX:PAB) has raised $3.4 million in new capital to fund the development of its prospective antibody-based cancer treatments.
Patrys has announced the allocation of 113.5 million new shares at $0.03 per share through an oversubscribed placement.
The funds will be used to fund trials of its products, including the final stages of a phase I trial for use of its PAT-SM6 product as a melanoma treatment.
The same product also the subject of a phase I/IIa clinical trial as a treatment for multiple myeloma – a type of bone marrow cancer.
Patrys also plans to use the windfall to help fund preclinical development of another antibody which has shown promise as a potential treatment for colon, lung, breast, ovarian and pancreatic cancers.
The company is also in the process of commercialising its most advanced product, gastric cancer treatment, PAT-SC1, and will use the placement funds to support business development and licensing activities.
Though Patrys' headquarters are in Melbourne, its main R&D centre is in Würzburg, Germany. The company was listed on the ASX in 2007.
Patrys (ASX:PAB) shares rose 8.11% in Monday's trading to $0.040. The stock price has generally been trending down since July.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
